Research
FORUM TRANSCRIPT

Illumina – Grail Integration Dynamics & 2022 Growth Outlook

  • Multi Asset
  • Healthcare
  • Global
PREMIUM

Specialist

Former director at Illumina Inc

Agenda

  • Recent developments around Illumina’s (NASDAQ: ILMN) acquisition of Grail, including outlook, potential integration challenges and liquid biopsy opportunity
  • Sequencing industry trends and competitive landscape, including Pacific Biosciences (NASDAQ: PACB) and Oxford Nanopore
  • Illumina's expansion into clinical genomics and recent partnership with SomaLogic (NASDAQ: SLGC) to expand in proteomic solutions
  • 2022 outlook – growth expectations, strategic assessments and AGBT (Advances in Genome Biology and Technology) General Meeting

Questions

For access to this and thousands of other Transcripts, request a free trial

Request A Demo